Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101


The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.

Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR.

NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016.


Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.


Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N.

J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. Epub 2017 Apr 11.


The hedgehog pathway in triple-negative breast cancer.

Habib JG, O'Shaughnessy JA.

Cancer Med. 2016 Oct;5(10):2989-3006. doi: 10.1002/cam4.833. Epub 2016 Aug 18. Review.


Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.

Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF.

Cancer Med. 2016 Aug;5(8):1897-907. doi: 10.1002/cam4.761. Epub 2016 Jun 23. Review.


Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.

Yardley DA, Bosserman LD, O'Shaughnessy JA, Harwin WN, Morgan SK, Priego VM, Peacock NW, Bass JD, Burris HA 3rd, Hainsworth JD.

Breast Cancer Res Treat. 2015 Nov;154(1):89-97. doi: 10.1007/s10549-015-3599-5. Epub 2015 Oct 12.


Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

Millis SZ, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, O'Shaughnessy JA.

Clin Breast Cancer. 2015 Dec;15(6):473-481.e3. doi: 10.1016/j.clbc.2015.04.008. Epub 2015 Apr 28.


Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.

Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL.

Mol Cell Proteomics. 2015 Jul;14(7):1959-76. doi: 10.1074/mcp.M115.049783. Epub 2015 May 7.


Highlights in metastatic breast cancer from the 2013 San Antonio Breast Cancer Symposium (SABCS): commentary.

O'Shaughnessy JA.

Clin Adv Hematol Oncol. 2014 Mar;12 Suppl 7(3):17-22. No abstract available.


"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.

Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder TA, Olivo M, Song J, O'Shaughnessy JA, Jove M, Perez EA.

Breast Cancer Res. 2015 Dec 9;17(1):150. doi: 10.1186/s13058-015-0657-1.


Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.

Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, Huw LY, Abbas I, Gower A, Schleifman EB, Desai R, Fu L, Sumiyoshi T, O'Shaughnessy JA, Hampton GM, Lackner MR.

Breast Cancer Res Treat. 2014 Nov;148(2):315-25. doi: 10.1007/s10549-014-3163-8. Epub 2014 Oct 22.


BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.

Robinson SD, O'Shaughnessy JA, Cowey CL, Konduri K.

Lung Cancer. 2014 Aug;85(2):326-30. doi: 10.1016/j.lungcan.2014.05.009. Epub 2014 May 21.


Highlights in metastatic breast cancer from the 2013 San Antonio Breast Cancer Symposium (SABCS).

O'Shaughnessy JA.

Clin Adv Hematol Oncol. 2014 Mar;12(3 Suppl 7):3-17. No abstract available.


Clinical roundtable monograph: effective management of quality of life in metastatic breast cancer.

Christopher T, Gradishar WJ, O'Shaughnessy JA, Bramsen B, Lurie RH.

Clin Adv Hematol Oncol. 2014 Feb;12(2 Suppl 4):1-14; quiz 15.


Effective management of quality of life in metastatic breast cancer.

O'Shaughnessy JA.

Clin Adv Hematol Oncol. 2014 Feb;12 Suppl 4(2):10-2. No abstract available.


Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.

Holmes FA, Espina V, Liotta LA, Nagarwala YM, Danso M, McIntyre KJ, Osborne CR, Anderson T, Krekow L, Blum JL, Pippen J, Florance A, Mahoney J, O'Shaughnessy JA.

BMC Res Notes. 2013 Dec 5;6:507. doi: 10.1186/1756-0500-6-507.


Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.

Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD.

Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.


Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trial.

Shen K, Qi Y, Song N, Tian C, Rice SD, Gabrin MJ, Brower SL, Symmans WF, O'Shaughnessy JA, Holmes FA, Asmar L, Pusztai L.

BMC Med Genomics. 2012 Nov 16;5:51. doi: 10.1186/1755-8794-5-51.


Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.

O'Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert NJ, Harbeck N.

Oncologist. 2012;17(4):476-84. doi: 10.1634/theoncologist.2011-0281. Epub 2012 Mar 14. Review.


Breast cancer in focus: treatment options for triple-negative metastatic breast cancer.

O'Shaughnessy JA.

Clin Adv Hematol Oncol. 2012 Jan;10(1):43-5. No abstract available.


Supplemental Content

Loading ...
Support Center